Literature DB >> 21636117

Long-term outcomes in pediatric-onset esophageal eosinophilia.

Charles W DeBrosse1, James P Franciosi, Eileen C King, Bridget K Buckmeier Butz, Allison B Greenberg, Margaret H Collins, J Pablo Abonia, Amal Assa'ad, Philip E Putnam, Marc E Rothenberg.   

Abstract

BACKGROUND: Pediatric eosinophilic esophagitis (EoE) is a newly recognized antigen-induced form of chronic esophagitis (CE).
OBJECTIVE: Characterization of long-term clinical outcomes in patients with pediatric EoE is needed.
METHODS: From histologic review of 3817 pediatric esophageal biopsy specimens from 1982-1999, we conducted a nested case-control study of patients with retrospectively identified histologic eosinophilic esophagitis (rEoE) and CE, as well as an age-matched control cohort. Participants were asked to complete validated health-related outcome questionnaires.
RESULTS: At an average of 15 years after initial endoscopy, both cohorts (42/198 patients with rEoE and 67/468 patients with CE, as well as 100 age-matched control subjects) completed questionnaires. Compared with control subjects, quality of life was significantly decreased among patients with rEoE (P < .001) and patients with CE (P < .001). Rates of dysphagia (patients with rEoE, 49%; patients with CE, 37%; control subjects, 6%) and food impaction (patients with rEoE, 40%; patients with CE, 14%; control subjects, 3%) were significantly increased in the rEoE cohort compared with those seen in control subjects (P < .001 and P < .001, respectively). Increased esophageal eosinophil counts (odds ratio [OR], 1.6; 95% CI, 1.1-2.5; P < .05) during childhood were predictive of dysphagia during early adulthood. Food allergy (OR, 2.7; 95% CI, 1.2-6.0; P < .01), allergic rhinitis (OR, 3.5; 95% CI, 1.8-6.8; P < .001), and asthma (OR, 2.1; 95% CI, 1.04-4.3; P = .04) were associated with dysphagia. Food impaction was more common among patients with reported food allergy than among those without (OR, 3.1; 95% CI, 1.2-7.8; P = .02).
CONCLUSIONS: Esophageal eosinophilia is associated with reduced quality of life and persistent symptoms 15 years after presentation. Increased esophageal eosinophil counts and the occurrence of food allergy and atopy in childhood increase the rate of dysphagia in young adulthood.
Copyright © 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21636117      PMCID: PMC3130990          DOI: 10.1016/j.jaci.2011.05.006

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  27 in total

1.  The SF-12 in the Australian population: cross-validation of item selection.

Authors:  Kristy Sanderson; Gavin Andrews
Journal:  Aust N Z J Public Health       Date:  2002-08       Impact factor: 2.939

2.  Eosinophilic esophagitis.

Authors:  Richard J Noel; Philip E Putnam; Marc E Rothenberg
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

3.  Eosinophilic esophagitis: a 10-year experience in 381 children.

Authors:  Chris A Liacouras; Jonathan M Spergel; Eduardo Ruchelli; Ritu Verma; Maria Mascarenhas; Edisio Semeao; Jonathan Flick; Janice Kelly; Terry Brown-Whitehorn; Petar Mamula; Jonathan E Markowitz
Journal:  Clin Gastroenterol Hepatol       Date:  2005-12       Impact factor: 11.382

4.  Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment.

Authors:  B Gandek; J E Ware; N K Aaronson; G Apolone; J B Bjorner; J E Brazier; M Bullinger; S Kaasa; A Leplege; L Prieto; M Sullivan
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

5.  Changing indications for upper endoscopy in children during a 20-year period.

Authors:  James P Franciosi; Kristin Fiorino; Eduardo Ruchelli; Justine Shults; Jonathan Spergel; Chris A Liacouras; Mary Leonard
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-10       Impact factor: 2.839

6.  Validation of prostate cancer index and SF-12 short forms.

Authors:  Thierry Lebeau; Paul Perrotte; Luc Valiquette; François Bénard; Michael McCormack; Fred Saad; Pierre I Karakiewicz
Journal:  Can J Urol       Date:  2005-12       Impact factor: 1.344

Review 7.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

Review 8.  Gastroesophageal reflux disease: then and now.

Authors:  Irvin M Modlin; Steven F Moss; Mark Kidd; Kevin D Lye
Journal:  J Clin Gastroenterol       Date:  2004 May-Jun       Impact factor: 3.062

9.  Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years.

Authors:  Alex Straumann; Hans-Peter Spichtin; Leticia Grize; Kathleen A Bucher; Christoph Beglinger; Hans-Uwe Simon
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

Review 10.  Proton pump inhibitors in children: a review.

Authors:  F Marchetti; T Gerarduzzi; A Ventura
Journal:  Dig Liver Dis       Date:  2003-10       Impact factor: 4.088

View more
  43 in total

Review 1.  Epidemiology and Natural History of Eosinophilic Esophagitis.

Authors:  Evan S Dellon; Ikuo Hirano
Journal:  Gastroenterology       Date:  2017-08-01       Impact factor: 22.682

Review 2.  Management of proton pump inhibitor responsive-esophageal eosinophilia and eosinophilic esophagitis: controversies in treatment approaches.

Authors:  Bharati Kochar; Evan S Dellon
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-12       Impact factor: 3.869

Review 3.  The Immunologic Mechanisms of Eosinophilic Esophagitis.

Authors:  David A Hill; Jonathan M Spergel
Journal:  Curr Allergy Asthma Rep       Date:  2016-02       Impact factor: 4.806

4.  A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease.

Authors:  Evan S Dellon; Hannah P Kim; Sarah L W Sperry; David A Rybnicek; John T Woosley; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2013-11-23       Impact factor: 9.427

5.  Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March.

Authors:  David A Hill; Robert W Grundmeier; Mark Ramos; Jonathan M Spergel
Journal:  J Allergy Clin Immunol Pract       Date:  2018-06-25

Review 6.  Eosinophilic esophagitis: allergic contribution, testing, and management.

Authors:  Amindra A Arora; Catherine R Weiler; David A Katzka
Journal:  Curr Gastroenterol Rep       Date:  2012-06

7.  Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD).

Authors:  Bruce S Bochner; Wendy Book; William W Busse; Joseph Butterfield; Glenn T Furuta; Gerald J Gleich; Amy D Klion; James J Lee; Kristin M Leiferman; Michael Minnicozzi; Redwan Moqbel; Marc E Rothenberg; Lawrence B Schwartz; Hans-Uwe Simon; Michael E Wechsler; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

Review 8.  Advances in clinical management of eosinophilic esophagitis.

Authors:  Evan S Dellon; Chris A Liacouras
Journal:  Gastroenterology       Date:  2014-08-07       Impact factor: 22.682

9.  Epidemiology of eosinophilic esophagitis.

Authors:  Evan S Dellon
Journal:  Gastroenterol Clin North Am       Date:  2014-03-19       Impact factor: 3.806

10.  Characterization of eosinophilic esophagitis murine models using optical coherence tomography.

Authors:  Aneesh Alex; Mario Noti; Elia D Tait Wojno; David Artis; Chao Zhou
Journal:  Biomed Opt Express       Date:  2014-01-27       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.